CNS Pharmaceuticals logo
CNS Pharmaceuticals CNSP
$ 3.56 -13.38%
report update icon

Quarterly report 2026-Q3
added 11-16-2026

CNS Pharmaceuticals Net Income | CNSP

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income CNS Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-15.9 M -14.9 M -18.9 M -15.3 M -14.5 M -9.46 M -3.88 M -7.39 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-3.88 M -18.9 M -12.5 M

Quarterly Net Income CNS Pharmaceuticals

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-2.5 M -2.59 M -4.94 M -5.96 M -3.22 M -2.38 M -4.3 M -3.18 M -5.61 M -2.53 M -3.54 M -5.38 M -4.52 M -4.02 M -4.93 M - -3.42 M -3.57 M -3.15 M - -3.81 M -3.81 M -3.61 M -3 M -2.01 M -2.47 M -1.97 M - -707 K -432 K -212 K - -193 K -257 K -310 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-193 K -5.96 M -2.98 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
-17.9 M $ 2.74 -5.03 % $ 29.2 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
-204 M $ 2.56 -6.07 % $ 432 M singaporeSingapore
XBiotech XBiotech
XBIT
-45.5 M $ 1.75 4.17 % $ 53.4 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
-1.03 M $ 1.37 -7.43 % $ 922 M israelIsrael
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
-7.98 M $ 3.15 -35.42 % $ 2.11 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
147 M $ 13.18 -1.2 % $ 3.14 B usaUSA
Exicure Exicure
XCUR
-4.95 M $ 0.96 -7.24 % $ 6.05 M usaUSA
Xencor Xencor
XNCR
-91.9 M $ 33.48 -1.56 % $ 2.49 B usaUSA
Cortexyme Cortexyme
CRTX
-84 M - -1.05 % $ 67.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
62.6 M $ 3.24 -5.55 % $ 710 M britainBritain
Daré Bioscience Daré Bioscience
DARE
-13.4 M $ 0.41 -9.93 % $ 4.58 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
-136 M $ 0.92 -9.07 % $ 109 M usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
-19.4 M $ 19.09 -3.54 % $ 258 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
317 M $ 91.28 -1.89 % $ 10.9 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
457 M $ 13.18 -2.04 % $ 11.3 B chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
-1.36 M - - $ 5.72 M chinaChina
iBio iBio
IBIO
-32.8 M $ 0.83 3.01 % $ 86.4 M usaUSA
Kodiak Sciences Kodiak Sciences
KOD
-230 M $ 97.05 -0.87 % $ 5.16 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
-196 M $ 0.02 -56.5 % $ 219 usaUSA
FSD Pharma FSD Pharma
HUGE
-27 M - 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
452 K $ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
214 M - - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
-153 M $ 28.91 -8.89 % $ 1.39 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
9.88 M $ 13.01 0.74 % $ 1.16 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-105 M - 1052.0 % $ 415 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
-43.1 M - - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-10.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-19.2 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-155 M - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-22.4 M - 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-49.9 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-43.4 M - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
22.4 M - - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
-106 M - - $ 269 M usaUSA
AVROBIO AVROBIO
AVRO
-74.2 B - 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
10.2 B - - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-10.3 M - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
287 M - 0.49 % $ 251 B cayman-islandsCayman-islands
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
-232 M $ 0.23 -12.11 % $ 16.8 K usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
-9.89 M - - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-18.2 M - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
17.4 M - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-17 M - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-405 K - -5.98 % $ 34.1 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
-27 M - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
-3.75 M - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-3.56 M - - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-22.7 M - - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
391 K - 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
-45.3 M - 49.81 % $ 13.2 M usaUSA